Health Trials

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

ConditionsSoft Tissue SarcomaClear Cell SarcomaEpithelioid SarcomaPerivascular Epithelioid Cell NeoplasmsDesmoplastic Small Round Cell TumorMalignant Solitary Fibrous TumorsAlveolar Soft Part SarcomaEpithelioid HemangioendotheliomaLow Grade Fibromyxoid SarcomaSclerosing Epithelioid Fibrosarcoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Claudius Regaud

About this trial

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype.

400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol.

Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

Eligibility criteria

Qualifiers

Age ≥18 years at the time of study entry.

Clear Cell Sarcoma (CCS)

Epithelioid Sarcoma (ES)

Perivascular Epithelioid Cell neoplasm (PEComa)

Disqualifiers

Diagnosis of all other histotypes of soft tissue sarcoma.

Any condition contraindicated with procedures required by the protocol.

Known history of positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.

Trial design

Treatments tested in this trial

  • Patient with Soft Tissue Sarcoma

Treatment groups

400 Participants
are divided into 1 treatment group

Sponsors and collaborators

Institut Claudius Regaud

Lead sponsor

Source ClinicalTrials.gov